Gurnee, IL, August 3, 2009
Essential CRO and Ecron Acunova have announced the formation of a global strategic alliance. The alliance network is established through a combination of Essential CRO’s presence in Gurnee, Illinois with Ecron Acunova, based in Bangalore, India with its U.S. office in Princeton, NJ and an established presence, headquartered in Frankfurt, Germany, across 14 countries in Europe.
While Essential and Ecron Acunova have been partners for several years, the magnitude of project size and positive feedback from sposors on the combined team execution have influenced the establishment of this alliance. The alliance has passed several international clients QA audits over the past two years reinforcing the quality of execution. In the past six months the alliance has won global projects in the eight figure range in over 14 countries from leading mid-sized biotech and large pharma sponsors.
About Essential
Essential provides CRO and patient recruitment services. The organization’s two main service offerings of CRO and patient recruitment services are independent, yet fully integrated. Visit www.essentialgroupinc.com for more information.
About Ecron Acunova
Ecron Acunova is headquartered in Bangalore, India with European HQ in Frankfurt, Germany and US HQ in Princeton, NJ. Ecron Acunova provides services for Phase I–IV clinical research, including Clinical Trial Management, Clinical Data Management, PK/PD services and Central Lab with its research centers in Germany and India. Ecron Acunova provides clinical development services to the pharmaceutical, biotechnology, nutritional, device and medical diagnostics industries. Visit www.ecronacunova.com for more information.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.